CRISPR/Cas9 Ablated BCL11A Unveils the Genes with Possible Role of Globin Switching.

ABSTRACT:

Purpose

Fetal hemoglobin (HbF) upregulation is a mitigating factor in β-hemoglobinopathies therapy like β-thalassemia and sickle cell diseases. Finding molecular mechanisms and the key regulators responsible for globin switching could be helpful to develop effective ways to HbF upregulation. In our prior in silico report, we identified a few factors that are likely to be responsible for globin switching. The goal of this study is to experimentally validate the factors.

Methods

We established K562 cell line with BCL11A knock down leading to increase in HBG1/2 using CRISPR/Cas9 system. Then, using quantitative polymerase chain reaction (qPCR), we determined the expression level of the factors which were previously identified in our prior in silico study.

Resul

SUBMITTER: Movahedi Motlagh F 

PROVIDER: S-EPMC10676543 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature